{"id":794449,"date":"2024-12-12T07:06:53","date_gmt":"2024-12-12T12:06:53","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conference\/"},"modified":"2024-12-12T07:06:53","modified_gmt":"2024-12-12T12:06:53","slug":"fennec-pharmaceuticals-to-participate-in-upcoming-investor-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conference\/","title":{"rendered":"Fennec Pharmaceuticals to Participate in Upcoming Investor Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">RESEARCH TRIANGLE PARK, N.C., Dec.  12, 2024  (GLOBE NEWSWIRE) &#8212; Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in the virtual H.C. Wainwright @ Home Fireside Chat Series taking place on Monday, December 16, 2024 at 11:00 a.m. ET.<\/p>\n<p align=\"justify\">To access the live webcast, please visit:\u00a0<a href=\"https:\/\/investors.fennecpharma.com\/events-and-presentations\/events\" rel=\"nofollow\" target=\"_blank\">https:\/\/investors.fennecpharma.com\/events-and-presentations\/events<\/a>. An archived replay of the webcast will be available on the Fennec website following the event.<\/p>\n<p align=\"justify\">\n        <strong>About\u00a0Fennec Pharmaceuticals<\/strong><br \/>\n        <br \/>Fennec Pharmaceuticals Inc.\u00a0is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK<sup>\u00ae<\/sup>\u00a0to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in\u00a0September 2022\u00a0and\u00a0European Commission\u00a0approval in\u00a0June 2023\u00a0and\u00a0U.K.\u00a0approval in\u00a0October 2023\u00a0under the brand name PEDMARQSI<sup>\u00ae<\/sup>. PEDMARK has received Orphan Drug Exclusivity in the\u00a0U.S.\u00a0and PEDMARQSI has received Pediatric Use Marketing Authorization in\u00a0Europe, which includes eight years plus two years of data and market protection. For more information, please visit\u00a0<a href=\"http:\/\/www.fennecpharma.com\/\" rel=\"nofollow\" target=\"_blank\">www.fennecpharma.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>For further information, please contact:<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Robert Andrade<br \/>Chief Financial Officer<br \/>Fennec Pharmaceuticals Inc.<br \/>+1 919-246-5299<\/p>\n<p align=\"justify\">\n        <strong>Corporate &amp; Media:<\/strong><br \/>\n        <br \/>Lindsay Rocco\u00a0<br \/>Elixir Health Public Relations<br \/>+1 862-596-1304<br \/><a href=\"mailto:lrocco@elixirhealthpr.com\" rel=\"nofollow\" target=\"_blank\">lrocco@elixirhealthpr.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxODEzNiM2NjM0MjIyIzIwODk4NTE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MmU2NGFmZWMtNzZkOS00ZDNiLTkwOGUtYmQ5MTUwMTkxYzBjLTExMDE0MjI=\/tiny\/Fennec-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>RESEARCH TRIANGLE PARK, N.C., Dec. 12, 2024 (GLOBE NEWSWIRE) &#8212; Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in the virtual H.C. Wainwright @ Home Fireside Chat Series taking place on Monday, December 16, 2024 at 11:00 a.m. ET. To access the live webcast, please visit:\u00a0https:\/\/investors.fennecpharma.com\/events-and-presentations\/events. An archived replay of the webcast will be available on the Fennec website following the event. About\u00a0Fennec Pharmaceuticals Fennec Pharmaceuticals Inc.\u00a0is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK\u00ae\u00a0to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in\u00a0September 2022\u00a0and\u00a0European Commission\u00a0approval in\u00a0June 2023\u00a0and\u00a0U.K.\u00a0approval in\u00a0October 2023\u00a0under the brand name PEDMARQSI\u00ae. PEDMARK has received Orphan &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Fennec Pharmaceuticals to Participate in Upcoming Investor Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-794449","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Fennec Pharmaceuticals to Participate in Upcoming Investor Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fennec Pharmaceuticals to Participate in Upcoming Investor Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"RESEARCH TRIANGLE PARK, N.C., Dec. 12, 2024 (GLOBE NEWSWIRE) &#8212; Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in the virtual H.C. Wainwright @ Home Fireside Chat Series taking place on Monday, December 16, 2024 at 11:00 a.m. ET. To access the live webcast, please visit:\u00a0https:\/\/investors.fennecpharma.com\/events-and-presentations\/events. An archived replay of the webcast will be available on the Fennec website following the event. About\u00a0Fennec Pharmaceuticals Fennec Pharmaceuticals Inc.\u00a0is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK\u00ae\u00a0to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in\u00a0September 2022\u00a0and\u00a0European Commission\u00a0approval in\u00a0June 2023\u00a0and\u00a0U.K.\u00a0approval in\u00a0October 2023\u00a0under the brand name PEDMARQSI\u00ae. PEDMARK has received Orphan &hellip; Continue reading &quot;Fennec Pharmaceuticals to Participate in Upcoming Investor Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-12T12:06:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxODEzNiM2NjM0MjIyIzIwODk4NTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Fennec Pharmaceuticals to Participate in Upcoming Investor Conference\",\"datePublished\":\"2024-12-12T12:06:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conference\\\/\"},\"wordCount\":207,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxODEzNiM2NjM0MjIyIzIwODk4NTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conference\\\/\",\"name\":\"Fennec Pharmaceuticals to Participate in Upcoming Investor Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxODEzNiM2NjM0MjIyIzIwODk4NTE=\",\"datePublished\":\"2024-12-12T12:06:53+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxODEzNiM2NjM0MjIyIzIwODk4NTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxODEzNiM2NjM0MjIyIzIwODk4NTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fennec Pharmaceuticals to Participate in Upcoming Investor Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Fennec Pharmaceuticals to Participate in Upcoming Investor Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conference\/","og_locale":"en_US","og_type":"article","og_title":"Fennec Pharmaceuticals to Participate in Upcoming Investor Conference - Market Newsdesk","og_description":"RESEARCH TRIANGLE PARK, N.C., Dec. 12, 2024 (GLOBE NEWSWIRE) &#8212; Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in the virtual H.C. Wainwright @ Home Fireside Chat Series taking place on Monday, December 16, 2024 at 11:00 a.m. ET. To access the live webcast, please visit:\u00a0https:\/\/investors.fennecpharma.com\/events-and-presentations\/events. An archived replay of the webcast will be available on the Fennec website following the event. About\u00a0Fennec Pharmaceuticals Fennec Pharmaceuticals Inc.\u00a0is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK\u00ae\u00a0to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in\u00a0September 2022\u00a0and\u00a0European Commission\u00a0approval in\u00a0June 2023\u00a0and\u00a0U.K.\u00a0approval in\u00a0October 2023\u00a0under the brand name PEDMARQSI\u00ae. PEDMARK has received Orphan &hellip; Continue reading \"Fennec Pharmaceuticals to Participate in Upcoming Investor Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2024-12-12T12:06:53+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxODEzNiM2NjM0MjIyIzIwODk4NTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Fennec Pharmaceuticals to Participate in Upcoming Investor Conference","datePublished":"2024-12-12T12:06:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conference\/"},"wordCount":207,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxODEzNiM2NjM0MjIyIzIwODk4NTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conference\/","name":"Fennec Pharmaceuticals to Participate in Upcoming Investor Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxODEzNiM2NjM0MjIyIzIwODk4NTE=","datePublished":"2024-12-12T12:06:53+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxODEzNiM2NjM0MjIyIzIwODk4NTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxODEzNiM2NjM0MjIyIzIwODk4NTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Fennec Pharmaceuticals to Participate in Upcoming Investor Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/794449","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=794449"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/794449\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=794449"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=794449"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=794449"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}